People: argenx SE (ARGX.BR)
Dr. Torsten Dreier is the Chief Development Officer of argenx SE since May 2008. He has been developing antibodies for more than 20 years and progressed six antibody products from preclinical research into clinical trials. Prior to joining argenx, he was Director of Therapeutic Drug Development and Senior Director Preclinical Development at Ablynx NV, with overall responsibility for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Between 1997-2003, Dr. Dreier worked as Director Preclinical Development at Micromet AG in Munich, Germany, on the preclinical characterization of recombinant antibodies and BiTEs. He holds a PhD in Biochemistry from the University of Tübingen, Germany. In 1995, he joined the group of Prof. Ralf A. Reisfeld at the Scripps Research Institute in La Jolla, CA as a postdoctoral researcher and extended his know-how in immunology with his work on immunocytokines (recombinant antibody cytokine fusion proteins), recombinant antibodies and cytokines.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|